Push/Pull

Push! Pull! Push! Pull! / Highlights from Davos 2018

Dear All: Three important documents were released at / during / around the World Economic Forum meeting that occurred this week in Davos. First and foremost, we have the final report from DRIVE-AB. It’s a substantial document and you’ll need to set aside an afternoon to read it. As a way to get started, my 11 Sep 2017

Read More »

G20 Health Minister’s declaration / Calls for push, pull, avoiding price/volume mechanisms, and support of global partnerships!

Dear All: Adding to the continued forward momentum of calls for support of antibiotic R&D, this week’s meeting of the G20 Health Ministers has led to the attached declaration. After some very sound recitations of the importance of health communities and the importance of good infrastructure, we also have calls for R&D preparedness (Para 15), workforce building (Para 22),

Read More »

Ardal et al. / Pull incentives for antibiotics – TATFAR analysis of 6 models

Dear All: ​The TATFAR group has a new and very helpful paper out in Clinical Infectious Diseases in which they analyze 6 different kinds of pull incentives: Higher reimbursement Diagnosis confirmation (lower cost for a few days of empiric therapy, higher cost if diagnostics confirm ongoing need) A fully delinked market entry reward (no sales-based income) A

Read More »

Heads-up on REVAMP, a credible Pull incentive for the US!

Dear All: Incredibly exciting news! Due to the bipartisan efforts of Representatives John Shimkus (R-IL) and Tony Cardenas (D-CA), the Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 is now being introduced. This is the Pull incentive that we’ve been looking for in the US! The very short summary is that REVAMP (a) creates a new “priority antimicrobial product” category, (b) grants

Read More »

Commissioner Gottleib (New FDA initiatives, need for Pull incentives) + updated Pew pipeline analyses

Dear All: It was a HUGE day at the Pew Charitable Trusts today! First, Commissioner Scott Gottleib gave a superb and very exciting speech. You can either read or listen to the entire speech. There is also a panel discussion after his talk that is worth replaying. Here are some highlights from Commissioner Gottleib’s talk: FDA is working to coordinate

Read More »

AMR stays on the G20’s to-do list with calls for Push and Pull mechanisms

Aside: Please look closely at the forward calendar. In addition to two new webinars from GARDP’s REVIVE project, there is a meeting in Thailand in December that focuses on alternatives to antibiotics. I’m told that the program is primarily focused on veterinary and agricultural uses, but previous year’s attendees have found the discussion to have broad application

Read More »
Scroll to Top